Earlier this week, the US Food and Drug Administration authorized the use of Remdesivir for patients in a state of emergency. As such, the federal government will start shipping tens of thousands of treatments across the country. Gilead Sciences, the company behind the investigational drug, decided as well to donate their existing supply. When asked whether it would occur a prioritization of the US market over others, the CEO and actual chairman, Daniel O'Day remarked: "I think we're aligned with the US government to both serve the patients here in the United States and then to be able to also make sure, as a global company based here in the United States, that we can serve other countries around the world as well."